½ÃÀ庸°í¼­
»óǰÄÚµå
1279054

¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : Á¦Ç°º°, ½Ã¼úº°, Áúº´ ÀûÀÀÁõº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(2022-2029³â)

Global Embolotherapy Market Size study & Forecast, by Product by Procedure, by Disease indication, by End user and Regional Analysis, 2022-2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

»öÀü¿ä¹ýÀº ´Ù¾çÇÑ ÁúȯÀ» Ä¡·áÇϱâ À§ÇØ »öÀüÁ¦¸¦ »ç¿ëÇÏ¿© Ç÷°ü°ú Ç÷·ù¸¦ Â÷´ÜÇÏ´Â ÃÖ¼Ò Ä§½ÀÀû ÀÇ·á ½Ã¼úÀÔ´Ï´Ù.

»öÀüÁ¦´Â °íü ÀÔÀÚ, Á© ¶Ç´Â ¾×ü·Î Ç÷°ü¿¡ Á÷Á¢ ÁÖÀԵǾî Ç÷°üÀ» ÀÀ°í½ÃÄÑ ½ÅüÀÇ Æ¯Á¤ ºÎÀ§·Î Ç÷¾×ÀÌ È帣Áö ¸øÇϵµ·Ï ¸·´Â´Ù. »öÀü¿ä¹ýÀº ÀڱñÙÁ¾, °£Á¾¾ç, µ¿¸Æ·ù, Ç÷°ü ±âÇü µî ´Ù¾çÇÑ ÁúȯÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌ ±â¼úÀº ±âÁ¸ ¼ö¼úº¸´Ù ´ú ħ½ÀÀûÀ̰í, °æ¿ì¿¡ µû¶ó¼­´Â ¿Ü·¡¿¡¼­ ½ÃÇàÇÒ ¼ö ÀÖÀ¸¸ç, ȸº¹ ½Ã°£ÀÌ Âª°í ÇÕº´Áõµµ ÀûÀº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº Àúħ½ÀÀû ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Àúħ½ÀÀû ¼ö¼ú¿¡ ´ëÇÑ À¯¸®ÇÑ »óȯ ½Ã³ª¸®¿À, »öÀü¿ä¹ý ÀåºñÀÇ ±â¼ú ¹ßÀüÀÔ´Ï´Ù.

Àúħ½ÀÀû ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â »öÀü¿ä¹ý ½ÃÀåÀÇ ¼ºÀåÀ» Áö¿øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »öÀü¿ä¹ýÀº ¾Ï, ÀڱñÙÁ¾, µ¿¸Æ·ù, Ç÷°ü ±âÇü µî ´Ù¾çÇÑ ÁúȯÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â ÃÖ¼Ò Ä§½ÀÀû ¹æ¹ýÀ¸·Î, Statista¿¡ µû¸£¸é 2019³â ¼¼°è ÃÖ¼Ò Ä§½À ¼ö¼ú ½ÃÀå ±Ô¸ð´Â 205¾ï ´Þ·¯·Î 2030³â¿¡´Â 440¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °á°úÀûÀ¸·Î, Àúħ½ÀÀû ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ½ÅÈï±¹ ½ÃÀåÀÇ È¯ÀÚ ¼ö Áõ°¡¿Í Á¤ºÎ ¹× ¹Î°£ ´ÜüÀÇ ÀÇ·á ¹× ÇコÄÉ¾î ½Ã¼³ °³¼±À» À§ÇÑ ÀÚ±Ý Á¶´Þ ¹× ÅõÀÚ Áõ°¡´Â ¿¹Ãø ±â°£ Áß ÀÌ ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ÃæºÐÇÑ Áõ°Å ºÎÁ·°ú ºÒ¸®ÇÑ ±ÔÁ¦ ½Ã³ª¸®¿À, ´ëü ¿ä¹ýÀÇ °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×Àº 2022-2029³âÀÇ ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¼¼°è »öÀüÁõ Ä¡·á ½ÃÀå Á¶»ç ´ë»ó ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, Áß³²¹Ì, ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç, À¯¸®ÇÑ »óȯ Á¤Ã¥, ½ÃÀå °³¹ßÀ» À§ÇÑ ÅõÀÚ Áõ°¡·Î ÀÎÇØ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á °ü±¤ Ȱ¼ºÈ­, ÀÇ·á ³×Æ®¿öÅ© °³¹ß, ¿¬±¸°³¹ß Ȱµ¿ Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ »öÀüÁõ Ä¡·á ½ÃÀå¿¡ À¯¸®ÇÑ ¼ºÀå Àü¸ÁÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¼ö³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡¿¡¼­ »ê¾÷ÀÇ ÁúÀû, ¾çÀû Ãø¸éÀ» ÅëÇÕÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ½º³À¼ô
  • ¼¼°è¡¤ºÎ¹®º° ½ÃÀå Ã߻ꡤ¿¹Ãø, 2019-2029³â
    • »öÀü¿ä¹ý ½ÃÀå, Áö¿ªº°, 2019-2029³â
    • »öÀü¿ä¹ý ½ÃÀå : Á¦Ç°º°, 2019-2029³â
    • »öÀü¿ä¹ý ½ÃÀå : ½Ã¼úº°, 2019-2029³â
    • »öÀü¿ä¹ý ½ÃÀå : Áúȯ ÀûÀÀÁõº°, 2019-2029³â
    • »öÀü¿ä¹ý ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, 2019-2029³â
  • ÁÖ¿ä µ¿Çâ
  • Ãß»ê ¹æ¹ý
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç

Á¦2Àå ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»çÀÇ ¸ñÀû
  • ½ÃÀåÀÇ Á¤ÀÇ¿Í ½ºÄÚÇÁ
    • Á¶»ç ´ë»ó ¹üÀ§
    • »ê¾÷ÀÇ ÁøÈ­
  • Á¶»ç ´ë»ó³â
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå ¿ªÇÐ

  • »öÀü¿ä¹ý ½ÃÀå ¿µÇ⠺м®(2019-2029³â)
    • ½ÃÀå ÃËÁø¿äÀÎ
      • Àúħ½À ¿Ü°ú¼ö¼úÀÇ ¼ö¿ä Áõ°¡
      • Àúħ½À¼ö¼ú¿¡ ´ëÇÑ À¯¸®ÇÑ »óȯ ½Ã³ª¸®¿À
      • »öÀü¿ä¹ý µð¹ÙÀ̽ºÀÇ ±â¼úÀû Áøº¸ÀÇ Áõ°¡
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
      • ÃæºÐÇÑ ¿¡ºñ´ø½ºÀÇ °á¿©¿Í ºÒ¸®ÇÑ ±ÔÁ¦ ½Ã³ª¸®¿À
      • ´ëü ¿ä¹ýÀÇ °­ÇÑ ½ÃÀå Æ÷Áö¼Å´×
    • ½ÃÀå ±âȸ
      • ´ë»ó ȯÀÚ ¼öÀÇ Áõ°¡
      • Á¤ºÎ±â°üÀ̳ª ¹Î°£±â¾÷º° ÀÚ±ÝÁ¶´Þ°ú ÅõÀÚÀÇ Áõ°¡

Á¦4Àå ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå : »ê¾÷ ºÐ¼®

  • Porter's 5 Force ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's 5 Force ¸ðµ¨ÀÇ ¹Ì·¡Àû ¾îÇÁ·ÎÄ¡(2019-2029³â)
  • PEST ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ¾÷°è Àü¹®°¡º° Àü¸Á
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð¡¤Á¦¾È

Á¦5Àå ¸®½ºÅ© Æò°¡ COVID-19ÀÇ ¿µÇâ

  • COVID-19°¡ ¾÷°è¿¡ ¹ÌÄ¡´Â ÀüüÀûÀÎ ¿µÇâ¿¡ °üÇÑ Æò°¡
  • COVID-19 ÀÌÀü°ú COVID-19 ÀÌÈÄ ½ÃÀå ½Ã³ª¸®¿À

Á¦6Àå ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå : Á¦Ç°º°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå, Á¦Ç°º°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå, Á¦Ç°º° ÃßÁ¤¡¤¿¹Ãø 2019-2029
  • »öÀü¿ä¹ý ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • »öÀüÁ¦
    • Áö¿ø µð¹ÙÀ̽º

Á¦7Àå ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå : ½Ã¼úº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå : ½Ã¼úº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå, ½Ã¼úº° ÃßÁ¤¡¤¿¹Ãø 2019-2029
  • »öÀü¿ä¹ý ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • °æÄ«Å×ÅÍ µ¿¸Æ»öÀü¿ä¹ý(TAE)
    • ¼±ÅÃÀû ³»ºÎ ¹æ»ç¼± Ä¡·á(SIRT)
    • °æµ¿¸ÆÀû È­ÇлöÀü¿ä¹ý(TACE)

Á¦8Àå ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå, Áúȯ ÀûÀÀÁõº°

  • ½ÃÀå ½º³À¼ô
  • ¿£º¸·Î¼¼¶óÇÇ ¼¼°è ½ÃÀå : Áúȯ ÀûÀÀÁõº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå, Áúȯ ÀûÀÀÁõº° ÃßÁ¤¡¤¿¹Ãø 2019-2029³â
  • »öÀü¿ä¹ý ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ¾Ï
    • ¸»ÃÊÇ÷°ü Áúȯ
    • ½Å°æ°è Áúȯ
    • ºñ´¢±â°è Áúȯ
    • ½ÅÀå Áúȯ
    • ¼ÒÈ­±â°è Áúȯ

Á¦9Àå ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ½ÃÀå ½º³À¼ô
  • ¿£º¸·Î¼¼¶óÇÇ ¼¼°è ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° ½ÇÀû¡¤ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ÃßÁ¤¡¤¿¹Ãø 2019-2029
  • »öÀü¿ä¹ý ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • º´¿ø
    • Áø·á¼Ò
    • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
    • ±âŸ

Á¦10Àå ¼¼°èÀÇ »öÀü¿ä¹ý ½ÃÀå : Áö¿ªº° ºÐ¼®

  • »öÀü¿ä¹ý ½ÃÀå, Áö¿ªº° ½ÃÀå ½º³À¼ô
  • ºÏ¹Ì
    • ¹Ì±¹
      • Á¦Ç°º° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
      • ½Ã¼úº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
      • Áúȯ ÀûÀÀÁõº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
      • ÃÖÁ¾»ç¿ëÀÚº° ÃßÁ¤¡¤¿¹Ãø, 2019-2029³â
    • ij³ª´Ù
  • À¯·´ÀÇ »öÀü¿ä¹ý ½ÃÀå ½º³À¼ô
    • U.K.
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ »öÀü¿ä¹ý ½ÃÀå ½º³À¼ô
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ »öÀü¿ä¹ý ½ÃÀå ½º³À¼ô
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä« Áö¿ª
  • ¼¼°èÀÇ ±âŸ Áö¿ª

Á¦11Àå °æÀï Á¤º¸

  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Imbiotechnologies Ltd.
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫 Á¤º¸(µ¥ÀÌÅÍ Á¦°ø °¡´ÉÇÑ °æ¿ì¸¸)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù °³¹ß »óȲ
    • Johnson & Johnson
    • Kaneka Corporation
    • Medtronic Plc
    • Meril Life Sciences Pvt. Ltd.
    • Merit Medical Systems, Inc.
    • Penumbra, Inc.
    • Simbionix USA Corporation
    • Sirtex Medical Limited
    • Stryker Corporation

Á¦12Àå Á¶»ç ÇÁ·Î¼¼½º

  • Á¶»ç ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • ¹ë¸®µ¥À̼Ç
    • ÃâÆÇ
  • Á¶»çÀÇ Æ¯Â¡
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
KSA 23.06.12

Global Embolotherapy Market is valued approximately at USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Embolotherapy is a minimally invasive medical procedure that involves the use of embolic agents to block blood vessels or blood flow in order to treat a variety of medical conditions. Embolic agents can be solid particles, gels, or liquids that are injected directly into a blood vessel, causing the vessel to clot and preventing blood from flowing to a specific area of the body. Embolotherapy is used to treat a variety of conditions, including uterine fibroids, liver tumors, aneurysms, and vascular malformations. The technique is minimally invasive than traditional surgery and can be performed on an outpatient basis in some cases, with shorter recovery times and fewer complications. The key factor driving the market growth is rising demand for the minimally invasive surgical procedures, favorable reimbursement scenario for minimally invasive surgeries and growing technological advancement in embolotherapy devices.

The rising demand for minimally invasive surgical procedures is anticipated to support the growth of the embolotherapy market. Embolotherapy is a minimally invasive technique used to treat a wide range of medical conditions, including cancer, uterine fibroids, aneurysms, and vascular malformations. According to Statista, in 2019, the minimally invasive surgery market globally was valued USD 20.5 billion and it is anticipated to reach USD 44.04 billion by 2030. As a result, the rising demand for the minimally invasive surgical procedures is anticipated to propel the market growth. Additionally, the growing target patient population and rising funding & investment by government and private organizations for the medical and health care facility development is anticipated to create the lucrative opportunity for the market during projected period. However, the lack of sufficient evidence & unfavorable regulatory scenario, and strong market positioning of alternative therapies stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Embolotherapy Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominates the market holding the largest market share, owing to the presence of key market players, favorable reimbursement policies, and growing investments for the healthcare facility development. Whereas, Asia Pacific is anticipated to exhibit fastest growing region during forecasted period over the forecast period, owing to factors such as booming medical tourism, developing healthcare network and increasing research and development activities in the region would create lucrative growth prospects for the Embolotherapy market across Asia Pacific region.

Major market players included in this report are:

  • Imbiotechnologies Ltd.
  • Johnson & Johnson
  • Kaneka Corporation
  • Medtronic Plc
  • Meril Life Sciences Pvt. Ltd.
  • Merit Medical Systems, Inc.
  • Penumbra, Inc.
  • Simbionix USA Corporation
  • Sirtex Medical Limited
  • Stryker Corporation

Recent Developments in the Market:

  • In 2021, Terumo Corporation has received FDA approval for the PMA Supplement for the WEB 17 System, a novel component of the WEB Aneurysm Embolisation System for the treatment of intracranial wide-neck bifurcation aneurysms.

Global Embolotherapy Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Product, Procedure, Disease indication, End user, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Product:

  • Embolic Agents
  • Support Devices

By Procedure:

  • Transcatheter Arterial Embolization (TAE)
  • Selective Internal Radiation Therapy (SIRT)
  • Trans arterial Chemoembolization (TACE)

By Disease indication:

  • Cancer
  • Peripheral Vascular Disease
  • Neurological Diseases
  • Urological
  • Nephrological Disorders
  • Gastrointestinal Disorders

By End user:

  • Hospitals
  • Clinics
  • Ambulatory Surgery Centers
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Embolotherapy Market, by region, 2019-2029 (USD Billion)
    • 1.2.2. Embolotherapy Market, by Product, 2019-2029 (USD Billion)
    • 1.2.3. Embolotherapy Market, by Procedure, 2019-2029 (USD Billion)
    • 1.2.4. Embolotherapy Market, by Disease indication, 2019-2029 (USD Billion)
    • 1.2.5. Embolotherapy Market, by End user, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Embolotherapy Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Embolotherapy Market Dynamics

  • 3.1. Embolotherapy Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising demand for the minimally invasive surgical procedures
      • 3.1.1.2. Favourable reimbursement scenario for minimally invasive surgeries
      • 3.1.1.3. Growing technological advancements in embolotherapy devices
    • 3.1.2. Market Challenges
      • 3.1.2.1. Lack of sufficient evidence & unfavorable regulatory scenario
      • 3.1.2.2. Strong market positioning of alternative therapies
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing target patient populations
      • 3.1.3.2. Rising funding & investment by government and private organizations

Chapter 4. Global Embolotherapy Market: Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economic
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Embolotherapy Market, by Product

  • 6.1. Market Snapshot
  • 6.2. Global Embolotherapy Market by Product, Performance - Potential Analysis
  • 6.3. Global Embolotherapy Market Estimates & Forecasts by Product 2019-2029 (USD Billion)
  • 6.4. Embolotherapy Market, Sub Segment Analysis
    • 6.4.1. Embolic Agents
    • 6.4.2. Support Devices

Chapter 7. Global Embolotherapy Market, by Procedure

  • 7.1. Market Snapshot
  • 7.2. Global Embolotherapy Market by Procedure, Performance - Potential Analysis
  • 7.3. Global Embolotherapy Market Estimates & Forecasts by Procedure 2019-2029 (USD Billion)
  • 7.4. Embolotherapy Market, Sub Segment Analysis
    • 7.4.1. Transcatheter Arterial Embolization (TAE)
    • 7.4.2. Selective Internal Radiation Therapy (SIRT)
    • 7.4.3. Trans arterial Chemoembolization (TACE)

Chapter 8. Global Embolotherapy Market, by Disease indication

  • 8.1. Market Snapshot
  • 8.2. Global Embolotherapy Market by Disease indication, Performance - Potential Analysis
  • 8.3. Global Embolotherapy Market Estimates & Forecasts by Disease indication 2019-2029 (USD Billion)
  • 8.4. Embolotherapy Market, Sub Segment Analysis
    • 8.4.1. Cancer
    • 8.4.2. Peripheral Vascular Disease
    • 8.4.3. Neurological Diseases
    • 8.4.4. Urological
    • 8.4.5. Nephrological Disorders
    • 8.4.6. Gastrointestinal Disorders

Chapter 9. Global Embolotherapy Market, by End user

  • 9.1. Market Snapshot
  • 9.2. Global Embolotherapy Market by End user, Performance - Potential Analysis
  • 9.3. Global Embolotherapy Market Estimates & Forecasts by End user 2019-2029 (USD Billion)
  • 9.4. Embolotherapy Market, Sub Segment Analysis
    • 9.4.1. Hospitals
    • 9.4.2. Clinics
    • 9.4.3. Ambulatory Surgery Centers
    • 9.4.4. Others

Chapter 10. Global Embolotherapy Market, Regional Analysis

  • 10.1. Embolotherapy Market, Regional Market Snapshot
  • 10.2. North America Embolotherapy Market
    • 10.2.1. U.S. Embolotherapy Market
      • 10.2.1.1. Product breakdown estimates & forecasts, 2019-2029
      • 10.2.1.2. Procedure breakdown estimates & forecasts, 2019-2029
      • 10.2.1.3. Disease indication breakdown estimates & forecasts, 2019-2029
      • 10.2.1.4. End user breakdown estimates & forecasts, 2019-2029
    • 10.2.2. Canada Embolotherapy Market
  • 10.3. Europe Embolotherapy Market Snapshot
    • 10.3.1. U.K. Embolotherapy Market
    • 10.3.2. Germany Embolotherapy Market
    • 10.3.3. France Embolotherapy Market
    • 10.3.4. Spain Embolotherapy Market
    • 10.3.5. Italy Embolotherapy Market
    • 10.3.6. Rest of Europe Embolotherapy Market
  • 10.4. Asia-Pacific Embolotherapy Market Snapshot
    • 10.4.1. China Embolotherapy Market
    • 10.4.2. India Embolotherapy Market
    • 10.4.3. Japan Embolotherapy Market
    • 10.4.4. Australia Embolotherapy Market
    • 10.4.5. South Korea Embolotherapy Market
    • 10.4.6. Rest of Asia Pacific Embolotherapy Market
  • 10.5. Latin America Embolotherapy Market Snapshot
    • 10.5.1. Brazil Embolotherapy Market
    • 10.5.2. Mexico Embolotherapy Market
    • 10.5.3. Rest of Latin America Embolotherapy Market
  • 10.6. Rest of The World Embolotherapy Market

Chapter 11. Competitive Intelligence

  • 11.1. Top Market Strategies
  • 11.2. Company Profiles
    • 11.2.1. Imbiotechnologies Ltd.
      • 11.2.1.1. Key Information
      • 11.2.1.2. Overview
      • 11.2.1.3. Financial (Subject to Data Availability)
      • 11.2.1.4. Product Summary
      • 11.2.1.5. Recent Developments
    • 11.2.2. Johnson & Johnson
    • 11.2.3. Kaneka Corporation
    • 11.2.4. Medtronic Plc
    • 11.2.5. Meril Life Sciences Pvt. Ltd.
    • 11.2.6. Merit Medical Systems, Inc.
    • 11.2.7. Penumbra, Inc.
    • 11.2.8. Simbionix USA Corporation
    • 11.2.9. Sirtex Medical Limited
    • 11.2.10. Stryker Corporation

Chapter 12. Research Process

  • 12.1. Research Process
    • 12.1.1. Data Mining
    • 12.1.2. Analysis
    • 12.1.3. Market Estimation
    • 12.1.4. Validation
    • 12.1.5. Publishing
  • 12.2. Research Attributes
  • 12.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦